SynthesisPLoS neglected tropical diseases2023
The species distribution and antimicrobial resistance profiles of Nocardia species in China: A systematic review and meta-analysis.
Synthesis in PLoS neglected tropical diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 28 citations in OpenAlex.
- A landscape of epidemiology and strain distribution ofBiosafety and health · 2026Article
- Persistent CD4Frontiers in immunology · 2026Article
- Toxicity-guided dose modification for disseminatedFrontiers in pharmacology · 2026Article
- Clinical characteristics of pulmonary nocardiosis in patients with and without bronchiectasis: a single-center retrospective comparative study.Frontiers in cellular and infection microbiology · 2026Article
- When metagenomic next-generation sequencing detectsFrontiers in cellular and infection microbiology · 2026Article
- Case Report:Frontiers in medicine · 2026Article
- Epidemiology, clinical treatment and outcomes, susceptibility patterns and genotypic analysis of 214Frontiers in cellular and infection microbiology · 2026Article
- Molecular mechanisms underlyingFrontiers in cellular and infection microbiology · 2026Review
- Research progress on clinical challenges and prevention strategies of drug-resistantFrontiers in public health · 2026Review
- Nitric Oxide Contributes to the Pathogenesis ofMicroorganisms · 2025Article
- Article
- Clinical Features of Pulmonary Nocardiosis and Diagnostic Value of Metagenomic Next-Generation Sequencing: A Retrospective Study.Pathogens (Basel, Switzerland) · 2025Article
- A rare case of multiple brain abscesses caused by Nocardia abscessus co-infection with tuberculous meningitis in an immunocompetent patient.BMC infectious diseases · 2025Article
- Primary Cutaneous Nocardiosis (Lymphangitic Type) in an Immunocompetent Patient: A Case Report.Microorganisms · 2025Article
- An unveiling case of Nocardia pansinusitis in a patient with chronic lymphocytic leukemia: a case report.Journal of medical case reports · 2025Article
- Discovery of Novel Diagnostic Biomarkers for Common PathogenicPathogens (Basel, Switzerland) · 2025Article
- Epidemiology and Drug Resistance of Pulmonary Nocardiosis Among Tuberculosis-Suspected Patients in Guangzhou, China.Infection and drug resistance · 2025Article
- Overexpression of the major facilitator superfamily efflux pump geneFrontiers in cellular and infection microbiology · 2025Article
- Article
- Abdominal Abscesses Caused byInfection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNocardia species can cause local or disseminated infection. Prompt diagnosis and appropriate treatment of nocardiosis are required, because it can cause significant morbidity and mortality. Knowledge of local species distribution and susceptibility patterns is important to appropriate empiric therapy. However, knowledge on the epidemiology and antimicrobial susceptibility profiles of clinical Nocardia species remains limited in China.
methodsThe data of isolation of Nocardia species were collected from databases such as Pubmed, Web of Science, Embase as well as Chinese databases (CNKI, Wanfang and VIP). Meta-analysis was performed using RevMan 5.3 software. Random effect models were used and tested with Cochran's Q and I2 statistics taking into account the possibility of heterogeneity between studies.
resultsIn total, 791 Nocardia isolates were identified to 19 species levels among all the recruited studies. The most common species were N. farcinica (29.1%, 230/791), followed by N. cyriacigeorgica (25.3%, 200/791), N. brasiliensis (11.8%, 93/791) and N. otitidiscaviarum (7.8%, 62/791). N. farcinica and N. cyriacigeorgica were widely distributed, N. brasiliensis mainly prevalent in the south, N. otitidiscaviarum mainly distributed in the eastern coastal provinces of China. Totally, 70.4% (223/317) Nocardia were cultured from respiratory tract specimens, 16.4% (52/317) from extra-pulmonary specimens, and 13.3% (42/317) from disseminated infection. The proportion of susceptible isolates as follows: linezolid 99.5% (197/198), amikacin 96.0% (190/198), trimethoprim-sulfamethoxazole 92.9% (184/198), imipenem 64.7% (128/198). Susceptibility varied by species of Nocardia.
conclusionsN. farcinica and N. cyriacigeorgica are the most frequently isolated species, which are widely distributed in China. Pulmonary nocardiosis is the most common type of infection. Trimethoprim-sulfamethoxazole can still be the preferred agent for initial Nocardia infection therapy due to the low resistance rate, linezolid and amikacin could be an alternative to treat nocardiosis or a choice in a combination regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.